Cancer of the prostate diagnosis might be better with semen test


Prostate cancer is one of the most common cancers in men and a major cause of cancer-related deaths. Yet it is tricky to diagnose – the commonly used PSA test can result in over-

diagnosis and unnecessary further methods. Now, new information brought through the College of Adelaide

around australia offers to enhance the precision of cancer of the prostate diagnosis with the aid of

biomarkers in semen.

Writing within the journal Endocrine-Related Cancer, the scientists describe the way they

examined semen samples from 60 men and located small molecules known as

microRNAs were “remarkably accurate” at showing which men had cancer of the prostate and just how severe

it had been.

The issue using the current PSA (prostate specific antigen) test for cancer of the prostate is the fact that,

even though it is very sensitive, it’s not highly specific for cancer of the prostate. For example, it could

stay positive for non-cancerous conditions for example prostatic hyperplasia (BPH) and prostatitis.

This results in many unnecessary biopsies and, perhaps more seriously, in substantial over-diagnosis and over-treatment of slow-growing, non-lethal prostate cancers that are probably best

left alone and merely supervised within so-known as “careful waiting” regime.

“Biomarkers that may precisely identify cancer of the prostate in an initial phase and identify

aggressive growths are urgently required to improve patient care,” states lead author Dr. Luke Selth, a

Youthful Investigator from the Cancer Of The Prostate Foundation in america.

One biomarker could differentiate between higher and lower grade tumors

Once they examined the semen samples, they discovered numerous microRNAs known

to become elevated in cancer of the prostate. MicrosRNAs are small non-coding molecules which are important

for controlling gene expression.

PSA test

Unlike a PSA test, which is not highly specific for prostate cancer, microRNAs in seminal fluid samples could differentiate men with low tumors from those with higher grade tumors.

These were surprised to locate that a few of the microRNAs were better than the usual PSA test at

discovering which from the men had cancer and which didn’t.

Additionally they found just one microRNA – known as miR-200b – could differentiate men with low

growths from individuals with greater grade growths. “This will be significant,Inch describes Dr. Selth, “because, as

a possible prognostic tool, it can help to point the emergency and kind of treatment


In the past work, Dr. Selth and the team demonstrated that microRNAs within the bloodstream can predict which

men will probably experience recurrence after their cancer of the prostate continues to be surgically


He says they are “excited by the potential clinical application of microRNAs in a range of

body liquids,” and that he and the co-workers happen to be intending to validate their results with bigger

categories of patients.

Meanwhile, Medical News Today lately learned the way a commercial epigenetic test for

cancer of the prostate, when done alongside initial biopsy, precisely rules out the presence of

cancer as much as 88% of times.